Geulah Livshits
Stock Analyst at Chardan Capital
(3.26)
# 1,024
Out of 4,940 analysts
214
Total ratings
40.76%
Success rate
3.59%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geulah Livshits
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics | Maintains: Buy | $68 → $60 | $10.74 | +458.66% | 15 | Aug 11, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $12 → $11 | $2.92 | +276.71% | 20 | Aug 11, 2025 | |
| PRME Prime Medicine | Maintains: Buy | $12 → $10 | $3.51 | +184.90% | 6 | Aug 8, 2025 | |
| SNTI Senti Biosciences | Maintains: Buy | $12 | $1.52 | +689.47% | 10 | Aug 8, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $25 → $20 | $1.97 | +915.23% | 14 | Aug 8, 2025 | |
| TNYA Tenaya Therapeutics | Maintains: Buy | $9 | $0.68 | +1,221.20% | 12 | Aug 7, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $82 | $55.41 | +47.99% | 15 | Aug 5, 2025 | |
| KRYS Krystal Biotech | Maintains: Buy | $219 | $138.06 | +58.63% | 12 | Aug 5, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $25 | $5.53 | +352.08% | 11 | Aug 1, 2025 | |
| PASG Passage Bio | Maintains: Buy | $120 | $5.90 | +1,933.90% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 | $3.21 | +304.98% | 12 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $9 | $2.76 | +226.09% | 13 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $15 | $6.08 | +146.71% | 7 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $6 | $0.49 | +1,125.49% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $12 | $1.83 | +555.74% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $20 | $4.41 | +353.51% | 9 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $41.71 | +19.88% | 1 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.48 | - | 3 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.20 | - | 10 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $41 | $7.81 | +424.97% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $25 | $6.34 | +294.32% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $1.33 | +802.26% | 4 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $191 → $208 | $25.47 | +716.65% | 7 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $1.08 | +1,381.48% | 4 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $90 | $7.46 | +1,106.43% | 1 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $4 | $3.08 | +29.87% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $30 | $2.24 | +1,239.29% | 1 | Jul 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $9.66 | +86.34% | 1 | Oct 27, 2020 |
Intellia Therapeutics
Aug 11, 2025
Maintains: Buy
Price Target: $68 → $60
Current: $10.74
Upside: +458.66%
Rocket Pharmaceuticals
Aug 11, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $2.92
Upside: +276.71%
Prime Medicine
Aug 8, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $3.51
Upside: +184.90%
Senti Biosciences
Aug 8, 2025
Maintains: Buy
Price Target: $12
Current: $1.52
Upside: +689.47%
Iovance Biotherapeutics
Aug 8, 2025
Maintains: Buy
Price Target: $25 → $20
Current: $1.97
Upside: +915.23%
Tenaya Therapeutics
Aug 7, 2025
Maintains: Buy
Price Target: $9
Current: $0.68
Upside: +1,221.20%
CRISPR Therapeutics AG
Aug 5, 2025
Maintains: Buy
Price Target: $82
Current: $55.41
Upside: +47.99%
Krystal Biotech
Aug 5, 2025
Maintains: Buy
Price Target: $219
Current: $138.06
Upside: +58.63%
4D Molecular Therapeutics
Aug 1, 2025
Maintains: Buy
Price Target: $25
Current: $5.53
Upside: +352.08%
Passage Bio
Jun 24, 2025
Maintains: Buy
Price Target: $120
Current: $5.90
Upside: +1,933.90%
Jun 18, 2025
Maintains: Buy
Price Target: $13
Current: $3.21
Upside: +304.98%
May 29, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $2.76
Upside: +226.09%
May 19, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $6.08
Upside: +146.71%
May 16, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $0.49
Upside: +1,125.49%
May 15, 2025
Maintains: Buy
Price Target: $13 → $12
Current: $1.83
Upside: +555.74%
May 13, 2025
Maintains: Buy
Price Target: $22 → $20
Current: $4.41
Upside: +353.51%
Apr 9, 2025
Initiates: Buy
Price Target: $50
Current: $41.71
Upside: +19.88%
Jan 30, 2025
Downgrades: Neutral
Price Target: n/a
Current: $4.48
Upside: -
Dec 13, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.20
Upside: -
Aug 11, 2023
Reiterates: Buy
Price Target: $41
Current: $7.81
Upside: +424.97%
Mar 23, 2023
Maintains: Buy
Price Target: $28 → $25
Current: $6.34
Upside: +294.32%
Mar 22, 2023
Reiterates: Buy
Price Target: $12
Current: $1.33
Upside: +802.26%
Jan 18, 2023
Maintains: Neutral
Price Target: $191 → $208
Current: $25.47
Upside: +716.65%
Nov 15, 2022
Maintains: Buy
Price Target: $15 → $16
Current: $1.08
Upside: +1,381.48%
Nov 3, 2021
Maintains: Buy
Price Target: $100 → $90
Current: $7.46
Upside: +1,106.43%
Nov 3, 2021
Maintains: Neutral
Price Target: $5.5 → $4
Current: $3.08
Upside: +29.87%
Jul 23, 2021
Maintains: Neutral
Price Target: $50 → $30
Current: $2.24
Upside: +1,239.29%
Oct 27, 2020
Initiates: Buy
Price Target: $18
Current: $9.66
Upside: +86.34%